Evidence map›Paper›PMID 25978997›Full record

ArticleGlycobiology2015

Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells.

Kavitha Sivasubramaniyan, Abhishek Harichandan, Karin Schilbach, Andreas F Mack, Jens Bedke, Arnulf Stenzl, Lothar Kanz, Gerhard Niederfellner, Hans-Jörg Bühring

Open access · bronzeAbstract read
In one paragraph

Article in Glycobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?Diagnostics (Basel, Switzerland) · 2024
    Review
  14. Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. American journal of cancer research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kavitha SivasubramaniyanDepartment of Internal Medicine II, Division of Hematology, Immunology, Oncology, Rheumatology and Pulmonology, University Clinic of Tübingen, Tübingen, Germany.
Abhishek HarichandanDepartment of Internal Medicine II, Division of Hematology, Immunology, Oncology, Rheumatology and Pulmonology, University Clinic of Tübingen, Tübingen, Germany Department of Urology, University Clinic of Tübingen, Tübingen, Germany.
Karin SchilbachDepartment of Pediatric Stem Cell Transplantation, University Children's Hospital, Tübingen 72076, Germany.
Andreas F MackInstitute of Clinical Anatomy and Cell Analysis, Eberhard Karls University of Tübingen, Tübingen, Germany.
Jens BedkeDepartment of Urology, University Clinic of Tübingen, Tübingen, Germany.
Arnulf StenzlDepartment of Urology, University Clinic of Tübingen, Tübingen, Germany.
Lothar KanzDepartment of Internal Medicine II, Division of Hematology, Immunology, Oncology, Rheumatology and Pulmonology, University Clinic of Tübingen, Tübingen, Germany.
Gerhard NiederfellnerDiscovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany.
Hans-Jörg BühringDepartment of Internal Medicine II, Division of Hematology, Immunology, Oncology, Rheumatology and Pulmonology, University Clinic of Tübingen, Tübingen, Germany hans-joerg.buehring@uni-tuebingen.de.
University of Tübingen · DERoche Pharma AG (Germany) · DEUniversity Children's Hospital Tübingen · DE

Funding

Structural Basis of Immune Recognition of Glycosylated AntigensU54GM062116 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI SASISEKHARAN, RAM · 2001 to 2010
$80.3M
NIGMS NIH HHS GM62116NIGMS NIH HHS U54 GM062116
6 · The paper itself

Abstract

Stage-specific embryonic antigen-4 (SSEA-4) is a glycosphingolipid, which is overexpressed in some cancers and has been linked to disease progression. However, little is known about the functions of SSEA-4 and the characteristics of SSEA-4 expressing tumor cells. Our studies identified SSEA-4 expression on a subpopulation of cells in many solid tumor cell lines but not in leukemic cell lines. Fluorescence-activated cell sorting-sorted SSEA-4(+) prostate cancer cells formed fibroblast-like colonies with limited cell-cell contacts, whereas SSEA-4(-) cells formed cobblestone-like epithelial colonies. Only colonies derived from SSEA-4(+) cells were enriched for pluripotent embryonic stem cell markers. Moreover, major epithelial cell-associated markers Claudin-7, E-cadherin, ESRP1 and GRHL2 were down-regulated in the SSEA-4(+) fraction of DU145 and HCT-116 cells. Similar to cell lines, SSEA-4(+) primary prostate tumor cells also showed down-regulation of epithelial cell-associated markers. In addition, they showed up-regulation of epithelial-to-mesenchymal transition as well as mesenchymal markers. Furthermore, SSEA-4(+) cells escape from adhesive colonies spontaneously and form invadopodia-like migratory structures, in which SSEA-4, cortactin as well as active pPI3K, pAkt and pSrc are enriched and colocalized. Finally, SSEA-4(+) cells displayed strong tumorigenic ability and stable knockdown of SSEA-4 synthesis resulted in decreased cellular adhesion to different extracellular matrices. In conclusion, we introduce SSEA-4 as a novel marker to identify heterogeneous, invasive subpopulations of tumor cells. Moreover, increased cell-surface SSEA-4 expression is associated with the loss of cell-cell interactions and the gain of a migratory phenotype, suggesting an important role of SSEA-4 in cancer invasion by influencing cellular adhesion to the extracellular matrix.

Indexed as

Gene Expression Regulation, NeoplasticCadherinsCell AdhesionCell Line, TumorCell MovementClaudinsCortactinDNA-Binding ProteinsEpithelial CellsEpithelial-Mesenchymal TransitionExtracellular MatrixHumansMalePhosphatidylinositol 3-KinasesProstateProto-Oncogene Proteins c-aktCadherinsClaudinsCLDN7 protein, humanCortactinCTTN protein, humanDNA-Binding ProteinsESRP1 protein, humanGRHL2 protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA-Binding ProteinsRNA, Small Interferingsrc-Family Kinasesstage-specific embryonic antigen-4Stage-Specific Embryonic AntigensTranscription Factorsadhesionepithelial-to-mesenchymal transitioninvadopodiainvasionSSEA-4

Identifiers

PMID25978997
PMCPMC4565992
OpenAlexW2118223568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.